Inhibikase Therapeutics Inc 2025年季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (Unaudited) Condensed Consolidated Balance Sheets as of March 31, 2025 (Unaudited) and December 31, 2024Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March31, 2025 and 2024 (Unaudited)Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2025 and 2024 (Unaudited)3Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2025 and 2024 (Unaudited)5Notes to Unaudited Condensed Consolidated Financial Statements6 We own various United States (“U.S.”) federal trademark applications and unregistered trademarks, including our company nameand logo, that we use in connection with the operation of our business. This Quarterly Report on Form 10-Q (this “QuarterlyReport”) includes our trademarks and trade names which are protected under applicable intellectual property laws and are ourproperty. This Quarterly Report also contains trademarks, trade names and service marks of other companies, which are theproperty of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly From time to time, we may use our website, our LinkedIn account at https://www.linkedin.com/company/inhibikase-therapeutics/and our YouTube account at https://www.youtube.com/user/Inhibikase to distribute material information about us and forcomplying with our disclosure obligations under Regulation FD. Our financial and other material information is routinely posted toand accessible on the Investors section of our website, available athttps://www.inhibikase.com/. Investors are encouraged to reviewthe Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS All statements included or incorporated by reference in this Quarterly Report, other than statements or characterizations ofhistorical fact, are forward-looking statements. These forward-looking statements are based on our current expectations, estimates,approximations and projections about our industry and business, management’s beliefs, and certain assumptions made by us, all ofwhich are subject to change. Forward-looking statements can often be identified by words such as “anticipates,” “expects,”“intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “may,” “will,” “should,” “would,” “could,” “potential,”“continue,” “ongoing,” and similar expressions and variations or negatives of these words. These statements are not guaranteesof future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actualresults could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. These forward-looking statements include, among other things, statements about: •the success, cost and timing of our product development activities and clinical trials, including statements regarding thetiming of initiation and completion of studies or trials and related preparatory work, the period during which the results ofthe trials will become available, and our research and development programs;•our ability to initiate a Phase 2b trial in pulmonary arterial hypertension;•our ability to successfully complete any clinical trial;•our ability to successfully manufacture our product candidates for future clinical trials or for commercial use, if approved;•our ability to obtain and maintain regulatory approval, if obtained, for any product candidates;•the success of competing therapies that are or become available;•our ability to obtain funding for our operations, including funding necessary to complete further development andcommercialization of our product candidates;•the commercialization of our product candidates, if approved; •the potential for another pandemic, epidemic or outbreak of an infectious disease to disrupt our business plans, productdevelopment activities, ongoing clinical trials, including the timing and enrollment of patients, the health of our employeesand the strength of our supply chain; and PART I—FINANCIAL INFORMATION Inhibikase Therapeutics, Inc.Notes to Unaudited Condensed Consolidated Financial Statements 1.